Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
492.40    -7.00 (-1.40%)
Bid:
492.80
Ask:
493.40
Spread: 0.60 (0.122%)
Market Cap: £1.33b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Contract Win

29 Sep 2016 10:53

RNS Number : 2040L
Chemring Group PLC
29 September 2016
Β 

FOR IMMEDIATE RELEASE 29 SEPTEMBER 2016

Β 

ELECTRONIC WARFARE CONTRACT WIN

Β 

Chemring Group PLC ("Chemring" or "the Group"), is pleased to announce that its subsidiary Chemring Australia has been awarded an A$18 million contract by the Australian Department of Defence to supply Chemring's Resolve 3 electronic warfare manpack system.

Β 

Resolve 3 is the latest iteration of the highly successful, combat-proven, Resolve electronic surveillance system, designed and produced by UK-based Chemring Technology Solutions. Up to 50 man-portable systems will be delivered during the first 18 months of the contract, with the systems being assembled at Chemring Australia's facility at Mulgrave, Victoria.

Β 

Michael Flowers, Group Chief Executive of Chemring, commented: "Resolve 3 represents the latest in man-portable electronic surveillance capability and I am delighted that Chemring Australia has won this contract. This is the largest award that the Group has received for the Resolve system, growing Resolve's user-base to nine countries and builds on Chemring's position as a market leader in electronic warfare."

-ENDS-

Β 

For further information:

Β 

Michael Flowers Group Chief Executive, Chemring Group PLC 01794 833901

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

Β 

James White MHP Communications 0203 128 8100

Β 

Cautionary statement

Β 

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

Β 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

Β 

About Chemring Group

Β· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

Β· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

Β· Chemring is organised under three strategic product segments: Countermeasures, Sensors & Electronics, and Energetic Systems

Β· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

Β· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

Β 

www.chemring.co.uk

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRALLMLTMBITMLF
Date   Source Headline
7th Aug 20237:00 amRNSTransaction in Own Shares
4th Aug 20234:16 pmRNSDirector/PDMR Shareholding
4th Aug 20234:15 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSTransaction in Own Shares
3rd Aug 20237:00 amRNSTransaction in Own Shares
2nd Aug 20237:00 amRNSTransaction in Own Shares
1st Aug 20239:26 amRNSTotal Voting Rights
1st Aug 20237:00 amRNSShare buyback programme
3rd Jul 20237:00 amRNSDirector/PDMR Shareholding
21st Jun 20239:47 amRNSBlock listing Interim Review
13th Jun 20237:00 amRNSAppointment of non-executive director
6th Jun 20237:00 amRNSHalf year results to 30 April 2023
1st Jun 202310:28 amRNSTotal Voting Rights
24th May 20237:00 amRNSAppointment of Chief Financial Officer
2nd May 20232:51 pmRNSTotal Voting Rights
20th Apr 202312:02 pmRNSDirector Declaration
3rd Apr 20239:25 amRNSTotal Voting Rights
29th Mar 20237:00 amRNSContract Award
28th Mar 20233:29 pmRNSHolding(s) in Company
16th Mar 20234:23 pmRNSDoc re. Ordinary & Special Resolutions
15th Mar 20233:11 pmRNSResult of AGM
15th Mar 20237:00 amRNSAGM Trading Update
1st Mar 202310:33 amRNSTotal Voting Rights
24th Feb 20239:07 amRNSDirector Declaration
1st Feb 202310:10 amRNSTotal Voting Rights
24th Jan 20233:09 pmRNSDirector/PDMR Shareholding
23rd Jan 20237:00 amRNSDirectorate Change
16th Jan 202310:44 amRNSNotice of AGM
9th Jan 20237:10 amRNSDirector Declaration
3rd Jan 202310:54 amRNSTotal Voting Rights
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20223:41 pmRNSBlock listing Interim Review
14th Dec 202212:31 pmRNSDirector/PDMR Shareholding
14th Dec 202212:28 pmRNSDirector/PDMR Shareholding
14th Dec 202212:27 pmRNSDirector/PDMR Shareholding
14th Dec 202212:25 pmRNSDirector/PDMR Shareholding
14th Dec 202212:23 pmRNSDirector/PDMR Shareholding
14th Dec 202212:20 pmRNSDirector/PDMR Shareholding
13th Dec 20227:00 amRNSFinal Results
1st Dec 202210:01 amRNSTotal Voting Rights
11th Nov 20222:30 pmRNSHolding(s) in Company
1st Nov 202210:02 amRNSTotal Voting Rights
18th Oct 20224:17 pmRNSHolding(s) in Company
6th Oct 20227:00 amRNSTrading Update
3rd Oct 20221:55 pmRNSAdditional Listings
3rd Oct 20229:36 amRNSTotal Voting Rights
12th Sep 20229:00 amRNSNotice of Results
1st Sep 20229:13 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.